|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Ciambrone DE. Treatment decision-making among older women with breast cancer. J Women Aging 2006;18(4):31-47. Abstract
Citron ML et al. Dose-dense AC followed by paclitaxel is associated with moderate,
frequent anemia compared to sequential and/or less DD treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. Proc ASCO 2005;Abstract 620.
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Davidson N et al. Albumin-bound paclitaxel in metastatic breast cancer: Viewpoints.
Drugs 2006;66(7):949-50. Abstract
Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.
Hurria A et al. Geriatric assessment for oncologists: Rationale and future directions. Crit Rev Oncol Hematol 2006;59:211-7. Abstract
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with
docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
J Clin Oncol 2006;24:5381-7. Abstract
Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40.
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Presentation. San Antonio Breast Cancer Symposium 2005a;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract
Muss H et al. Toxicity of older and younger patients treated with intensive adjuvant chemotherapy for node-positive breast cancer: The CALGB experience.
Proc ASCO 2006;Abstract 559.
Muss H et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-81. Abstract
O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. The Oncologist 2005;10:20-9. Abstract
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Simon R, Norton L. The Norton-Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006;3:406-7. No abstract available
 |
 |
